Search Results 41-50 of 16660 for Emicizumab

  1. A Study of Everolimus with or without Bevacizumab for Treating Patients with Advanced Kidney Cancer that Progressed after First-Line Therapy - Mayo Clinic

    Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere ...

  2. Oncology (Medical) - Clinical trials

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  3. Inebilizumab-cdon (intravenous route) - Side effects & uses - Mayo Clinic

    Inebilizumab-cdon injection is used to treat neuromyelitis optic spectrum disorder (NMOSD), a rare disorder that causes inflammation of the nerves of the eyes ...

  4. Drugs and Supplements that Start with E - Mayo Clinic

    Emicizumab-kxwh (subcutaneous route). Emla. Also known as. Lidocaine and prilocaine (topical application route). Emo-Cort. Also known as. Hydrocortisone ...

  5. Clinical trials - Oncology (Medical)

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  6. Drugs and Supplements that Start with E - Mayo Clinic

    Emicizumab-kxwh (subcutaneous route). Emla. Also known as. Lidocaine and prilocaine (topical application route). Emo-Cort. Also known as. Hydrocortisone ...

  7. I-124 evuzamitide PET/CT Imaging for the Diagnosis of Cardiac Amyloidosis - Mayo Clinic

    Inclusion Criteria: Understands the study procedures and can give signed informed consent (as specified in Section 10.1.3), which includes compliance with ...

  8. A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors - Mayo Clinic

    Patients will be randomized to receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks or 50 mg etane rcept subcutaneously weekly. The anticipated time on ...

  9. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. Clinical trials - Oncology (Medical)

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...